Wednesday February 10 2010 |
Biotechnology feed
|
All feeds
Home
Marketing Services
Antibodies
Careers
Directories
Drugs
Events
Genes
InDepth
News
Reports
Videos
A-Z
Business
Health
Drugs
Sources
Americas
Europe
Asia
Cancer
Cardio-
Diabetes
Bird Flu
Swine Flu
Summaries
Post News
Search
BioNews - BioPortfolio's News Portal
New Drug Applications IND Headlines
Sign-up to BioPortfolio's
New Drug Application IND news alerts
.
Subscribe to
BioWatch News Email alerts
-
open
BioWatch PDF brochure
.
Publish your news
using BioNewsCast
- open
BioNewsCast PDF brochure
.
Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
Pharma Live:
similar ...
The eCTD Upgrade: Cross-Application Linking
Pharmaceutical Technology:
similar ...
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
Genetic Engineering News:
similar ...
TOPICA Pharmaceuticals' IND application accepted for the use of luliconazole
News-Medical.Net:
similar ...
FDA Accepts TOPICA'S Luliconazole IND To Begin Clinical Trials In Onychomycosis
Medical News Today:
similar ...
TOPICA's IND for onychomycosis antifungal agent accepted by FDA
News-Medical.Net:
similar ...
TOPICA's IND for onychomycosis antifungal agent accepted by FDA
News-Medical.Net:
similar ...
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism ..
PR inside:
similar ...
FDA Accepts TOPICA'S Luliconazole IND to Begin Clinical Trials in Onychomycosis
Pharmacy Choice:
similar ...
Omeros Announces National Institute On Drug Abuse's Support For Phase 2 Clinical Study In Addiction Program
Medical News Today:
similar ...
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
Genetic Engineering News:
similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Genetic Engineering News:
similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Forbes.com:
similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Street Insider:
similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
RBC Dain Rauscher:
similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Yahoo! Canada:
similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
NewsBlaze:
similar ...
BDSI to discuss planned BEMA Granisetron IND with the FDA
News-Medical.Net:
similar ...
Biocon files IND for IN105 oral insulin with USFDA
Moneycontrol.com:
similar ...
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers' Diarrhea
Pharmacy Choice:
similar ...
